Stockscreener 앱 받기
57.73
0.91%
0.019
전일 마감가:
$57.75
열려 있는:
$57.29
하루 거래량:
1.32M
Relative Volume:
0.41
시가총액:
$7.53B
수익:
$638.78M
순이익/손실:
$-22.66M
주가수익비율:
-331.03
EPS:
-0.1744
순현금흐름:
$122.18M
1주 성능:
+27.80%
1개월 성능:
+39.51%
6개월 성능:
+221.61%
1년 성능:
+329.44%
1일 변동 폭
$55.73
$59.48
1주일 범위
$44.39
$60.69
52주 변동 폭
$11.16
$60.69
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
57.83 | 7.52B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
241.15 | 39.23B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.08 | 11.81B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.00 | 9.85B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
104.70 | 8.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
Why 10x Genomics (TXG) Is Up 21.7% After Raising 2026 Outlook Despite Q2 Revenue Drop - simplywall.st
10x Genomics $TXG Shares Acquired by Sei Investments Co. - MarketBeat
US$49.54That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - directorstalkinterviews.com
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - stockstotrade.com
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - TradingKey
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - Yahoo Finance
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - Moomoo
10x Genomics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash - stocktitan.net
10x Genomics, Inc. 2026: Revenue $151.04M, EPS ($0.14) — 10-Q Summary - TradingView
10x Genomics $TXG Shares Sold by Janus Henderson Group PLC - MarketBeat
TXG|10X Genomics Inc|Price:58.260|Chg%:+6.230 - TradingKey
Has 10x Genomics Inc (TXG) Missed Earnings Expectations with Q2 - GuruFocus
10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Earnings call transcript: 10x Genomics tops Q2 2026 estimates, shares fall - Investing.com
Transcript : 10x Genomics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
10x Genomics Inc (TXG) Shares Fall 3.9% -- What GF Score of 58 T - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics falls 2% despite beating revenue estimates - Investing.com
10x Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M - marketscreener.com
Q2 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics Q2 Swings to Loss, Revenue Falls - marketscreener.com
10x Genomics Q2 2026: Revenue $151.0M, Gross Margin 74%, Raises 2026 Revenue Guide - TradingView
10x Genomics: Q2 Earnings Snapshot - AOL.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $151.0M, vs. FactSet Est of $146.7M - marketscreener.com
10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide - stocktitan.net
10x Genomics Reports Second Quarter 2026 Financial Results - marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
10X Genomics faces earnings test as revenue expected to decline By Investing.com - Investing.com Nigeria
10X Genomics faces earnings test as revenue expected to decline - Investing.com
10x Sued Over Spatial Genomics Patents by Caltech, Licensee (1) - Bloomberg Law News
10x Genomics (TXG) 10K Form and Latest SEC Filings 2026 - MarketBeat
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
10x Genomics, Inc. (TXG) - DirectorsTalk Interviews
58,083 Shares in 10x Genomics $TXG Acquired by Edgestream Partners L.P. - MarketBeat
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Jun 22 '26 |
Sale |
34.44 |
30,000 |
1,033,269 |
1,108,380 |
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
1.62%
0.64%
자본화:
|
볼륨(24시간):